Prabhudas Lilladher's research report on Indoco Remedies
Our FY26/FY27E EPS have been cut sharply to factor in low margins given ongoing remediation cost and lower sales across regulated markets. We downgrade stock to ‘Hold’ from ‘Accumulate’. Indoco Remedies’ (INDR) Q3FY25 EBITDA was much below our estimates due to muted international business and higher expenses. The warning letter issued for both units is expected to restrict growth, particularly in the US market. The company cited other expenses to remain elevated over next two quarters. Our numbers do factor in higher remediation cost till H1FY26.
Outlook
At CMP, the stock is trading at 3.5x EV/domestic sales based on FY26E. We expect 11% PAT CAGR over FY24- 27E. We downgrade stock to ‘Hold’ from ‘Accumulate’ rating with revised TP of Rs325 valuing at 21x FY27E EPS as we roll forward. Timely resolution of Goa facility Unit 2 is a key for re-rating.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.